Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.105 USD | +2.18% | +14.74% | -27.09% |
Mar. 25 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
Mar. 25 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.09% | 390M | |
+26.15% | 681B | |
+21.85% | 556B | |
-5.15% | 361B | |
+17.16% | 325B | |
+4.94% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-4.22% | 157B |
- Stock Market
- Equities
- ESPR Stock
- News Esperion Therapeutics, Inc.
- Morgan Stanley Trims Price Target on Esperion Therapeutics to $3 From $9, Maintains Equalweight Rating